Amphetamine-induced dyskinesia in the transplanted hemi-parkinsonian mouse

Journal of Parkinson's Disease

Volumn 2, Issue 2, 2012, Pages 107-113

  Smith, Gaynor A ^a   Heuer, Andreas ^b   Klein, Alexander ^c   Vinh, Ngoc Nga ^b   Dunnett, Stephen B ^b   Lane, Emma L ^d  

^a MCLEAN HOSPITAL   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

6 OHDA; amphetamine; dopamine; dyskinesia; GID; LID; mouse; Parkinson's disease; Transplantation

Indexed keywords

AMPHETAMINE; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CD1 MOUSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DYSKINESIA; LIMB MOVEMENT; MESENCEPHALON; MOUSE; MOUSE STRAIN; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; TRANSGENIC MOUSE; VENTRAL MESENCEPHALON;

ADRENERGIC AGENTS; AMPHETAMINE; ANIMALS; ANTIPARKINSON AGENTS; CELL TRANSPLANTATION; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; EMBRYO, MAMMALIAN; FUNCTIONAL LATERALITY; LEVODOPA; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; STEREOTYPED BEHAVIOR;

EID: 84864655534     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2012-12102     Document Type: Article

References (38)

1. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. The New England Journal of Medicine, 344, 710-719.
2. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. (1989)Humanfetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Archives of Neurology, 46, 615-631.
3. Madrazo I, LeonV, Torres C, Aguilera MC,Varela G, Alvarez F, et al. (1988) Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. The New England Journal of Medicine, 318, 51.
4. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 54, 403-414.
5. Redmond DE Jr (2002) Cellular replacement therapy for Parkinson's disease-where we are today? The Neuroscientist: A review journal bringing neurobiology, neurology and psychiatry, 8, 457-488.
6. Redmond DE Jr, Robbins RJ, Naftolin F, Marek KL, Vollmer TL, Leranth C, et al. (1993) Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: Preliminary results in four patients. Research publications - Association for Research in Nervous and Mental Disease, 71, 325-359.
7. Bjorklund A, & Stenevi U (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain research, 177, 555-560.
8. Bjorklund A, Stenevi U, Dunnett SB, & Iversen SD (1981) Functional reactivation of the deafferented neostriatum by nigral transplants. Nature, 289, 497-499.
9. Dunnett SB, Bjorklund A, Stenevi U, & Iversen SD (1981) Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Research, 215, 147-161.
10. Vinuela A, Hallett PJ, Reske-Nielsen C, Patterson M, Sotnikova TD, Caron MG, et al. (2008) Implanted reuptakedeficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain: A Journal of Neurology, 131, 3361-3379.
11. Lane EL, Winkler C, Brundin P, & Cenci MA (2006) The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiology of Disease, 22, 334-345.
12. Carlsson T, Winkler C, Lundblad M, Cenci MA, Bjorklund A, & Kirik D (2006) Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease, 21, 657-668.
13. Garcia J, Carlsson T, Dobrossy M, Nikkhah G, & Winkler C (2011) Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation. Exp Neurol, 232, 270-279.
14. Lane EL, Vercammen L, Cenci MA, & Brundin P (2009) Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp Neurol, 219, 355-358.
15. Lane EL, Brundin P, & Cenci MA (2009) Amphetamineinduced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of Disease, 35, 42-51.
16. FrancardoV, Recchia A, Popovic N, Andersson D, Nissbrandt H, & Cenci MA (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis, 42, 327-340.
17. Heuer A, Smith GA, Lelos MJ, Lane EL,&DunnettSB(2012) Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. Behav Brain Res, 228, 30-43.
18. Smith GA, Heuer A, Dunnett SB, & Lane EL (2012) Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II Predicting l-DOPA-induced dyskinesia. Behav Brain Res, 226, 281-292.
19. Grealish S, Mattsson B, Draxler P, & Bjorklund A (2010) Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci, 31, 2266-2278.
20. Thompson LH, Grealish S, Kirik D, & Bjorklund A (2009) Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. The European Journal of Neuroscience, 30, 625-638.
21. Veng LM, Bjugstad KB, Freed CR, Marrack P, Clarkson ED, Bell KP, et al. (2002) Xenografts of MHC-deficient mouse embryonic mesencephalon improve behavioral recovery in hemiparkinsonian rats. Cell Transplantation, 11, 5-16.
22. Zhou J, Date I, Sakai K, Yoshimoto Y, Furuta T, Asari S, et al. (1993) Xenogeneic dopaminergic grafts reverse behavioral deficits induced by 6-OHDA in rodents: Effect of 15-deoxyspergualin treatment. Neuroscience Letters, 163, 81-84.
23. Shimizu K, Yamada M, Matsui Y, Tamura K, Moriuchi S, &Mogami H (1990) Neural transplantation in mouse Parkinson's disease. Stereotactic and Functional Neurosurgery, 54-55, 353-357.
24. Brundin P, Widner H, Nilsson OG, Strecker RE, & Bjorklund A (1989) Intracerebral xenografts of dopamine neurons: The role of immunosuppression and the blood-brain barrier. Experimental Brain Research Experimentelle Hirnforschung Experimentation Cerebrale, 75, 195-207.
25. Shimizu K, Tsuda N, Okamoto Y, Matsui Y, Miyao Y, Tamura K, et al. (1988) Transplant-induced recovery from 6-OHDA lesions of the nigrostriatal dopamineneurones in mice. Acta Neurochirurgica Supplementum, 43, 149-153.
26. Cenci MA, & Lundblad M (2007) Ratings of L-DOPAinduced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci, Chapter 9, Unit 9 25.
27. Winkler C, Kirik D, Bjorklund A, & Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease, 10, 165-186.
28. Cenci MA, Lee CS, & Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci, 10, 2694-2706.
29. Westin JE, Andersson M, Lundblad M, & Cenci MA (2001) Persistent changes in striatal gene expression induced by longterm L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci, 14, 1171-1176.
30. Monville C, Torres EM, Pekarik V, Lane EL, & Dunnett SB (2009) Genetic, temporal and diurnal influences on L-dopainduced dyskinesia in the 6-OHDA model. Brain Res Bull, 78, 248-253.
31. Lane EL, Soulet D, Vercammen L, Cenci MA, & Brundin P (2008) Neuroinflammation in the generation of posttransplantation dyskinesia in Parkinson's disease. Neurobiol Dis, 32, 220-228.
32. Castilho RF, Hansson O, & Brundin P (2000) Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Progress in Brain Research, 127, 203-231.
33. Brundin P, Isacson O, Gage FH, Prochiantz A,&Bjorklund A (1986) The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting. Brain Research, 366, 346-349.
34. LowWC, Triarhou LC, KasedaY, Norton J,&GhettiB(1987) Functional innervation of the striatum by ventral mesencephalic grafts in mice with inherited nigrostriatal dopamine deficiency. Brain Research, 435, 315-321.
35. Witt TC, & Triarhou LC (1995) Transplantation of mesencephalic cell suspensions from wild-type and heterozygous Weaver mice into the denervated striatum: Assessing the role of graft-derived dopaminergic dendrites in the recovery of function. Cell Transplantation, 4, 323-333.
36. Grealish S, Jonsson ME, Li M, Kirik D, Bjorklund A, &Thompson LH (2010) The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain: A Journal of Neurology, 133, 482-495.
37. Steece-Collier K, Soderstrom KE, Collier TJ, Sortwell CE, &Maries-Lad E (2009) Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J Comp Neurol, 515, 15-30.
38. Stromberg I, Bickford P, & Gerhardt GA (2010) Grafted dopamine neurons: Morphology, neurochemistry, and electrophysiology. Progress in Neurobiology, 90, 190-197.